Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.
Abstract: The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided.
Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
Abstract: The invention provides cobalamin compounds linked to a neutron capture therapy target (e.g. Boron-10 or Gadolinium-157), and optionally linked to a detectable moiety, as well as pharmaceutical compositions comprising the compounds, and methods for using the compounds in medical diagnosis and therapy.
Type:
Grant
Filed:
October 16, 2000
Date of Patent:
October 19, 2004
Assignees:
Mayo Foundation for Medical Education & Research, Minnesota, Regents of the University
Inventors:
Douglas A. Collins, Henricus P. C. Hogenkamp
Abstract: A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.
Type:
Grant
Filed:
December 26, 2002
Date of Patent:
September 7, 2004
Assignee:
Idenix Pharmaceuticals, Inc.
Inventors:
Martin L. Bryant, Jean-Pierre Sommadossi
Abstract: The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds.
Type:
Grant
Filed:
October 2, 2001
Date of Patent:
August 17, 2004
Assignee:
Emory University
Inventors:
Susheng Wang, Dennis C. Liotta, James P. Snyder, Hariharan Venkatesan
Abstract: N-substituted dithiocarbamate esters, pharmaceutical compositions containing them, and methods of treating hyperproliferative disorders such as cancer by administering the N-substituted dithiocarbamate esters.
Type:
Grant
Filed:
March 21, 2001
Date of Patent:
June 8, 2004
Assignee:
AtheroGenics, Inc.
Inventors:
Russell M. Medford, Uday Saxena, Lee K. Hoong, Patricia K. Somers
Abstract: A process for treatment of a purified lipoprotein material to inactivate prions in a manner that does not substantially adversely affect the biological activity of the lipoprotein is provided that includes treating the lipoprotein prion composition with a solution of base at a pH of between 10 and 13 for a sufficient time to cause inactivation.
Type:
Grant
Filed:
October 9, 2001
Date of Patent:
June 1, 2004
Assignee:
Serologicals Royalty Company
Inventors:
Joseph G. Montalto, Thomas M. McCall, Judith A. Vollmer-Gash
Abstract: Solid phases of (−)-cis-FTC, which are designated herein as amorphous (−)-FTC and Forms II and III (−)-cis-FTC) are provided that can be distinguished from Form I (−)-cis-FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. A hydrated crystalline form of (±)-cis-FTC (i.e. racemic cis-FTC), and a dehydrated form of the hydrate, are also provided, and can similarly be distinguished from other forms of FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These FTC forms can be used in the manufacture of other forms of FTC, or in pharmaceutical compositions. Particularly preferred uses of these forms are in the treatment of HIV or hepatitis B.
Abstract: This invention provides a method of altering the metabolism of sphingolipids in a cell comprising contacting the cell with a fumonisin, or an analog thereof. The invention also provides a method of detecting the consumption of a fumonisin or a fumonisin analog in a subject comprising (A) detecting, in a sample from the subject, the state of the metabolic pathway of sphingolipids and (B) comparing the state of the metabolic pathway to that of a normal subject, the presence of a change in the state of the metabolic pathway indicating the consumption of a fumonisin or a fumonisin analog. Also provided is a method of detecting the presence of a fumonisin or fumonisin analog contamination in a sample from a food or feed comprising detecting a reaction of the metabolic pathway of sphingolipids, the presence of the reaction indicating the presence of a fumonisin or fumonisin analog contamination. Furthermore, novel fumonisin analogs and compositions comprising fumonisins and fumonisin analogs are provided.
Type:
Grant
Filed:
October 2, 2000
Date of Patent:
April 13, 2004
Assignee:
Emory University
Inventors:
Alfred H. Merrill, Jr., Elaine W. Wang, Dennis C. Liotta, Ronald T. Riley
Abstract: Disclosed are novel bicyclic tris(anhydride)s useful as intermediates in the synthesis of biologically active compounds, and the compounds which may be synthesized from such intermediates.
Type:
Grant
Filed:
November 13, 2001
Date of Patent:
March 30, 2004
Assignee:
Pharmasset, Ltd.
Inventors:
Krzysztof W. Pankiewicz, Krystyna Lesiak, Kyoichi A. Watanabe
Abstract: The invention as disclosed herein is a method and composition for the treatment of HIV in humans and other host animals, that includes the administration of an effective HIV treatment amount of a phenylindole as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier. The compounds of this invention either possess antiviral (i.e., anti-HIV) activity, or are metabolized to a compound that exhibits such activity.
Type:
Grant
Filed:
April 11, 2002
Date of Patent:
March 23, 2004
Assignee:
Idenix Pharmaceuticals, Inc.
Inventors:
Paulo LaColla, Marino Artico, Jean-Pierre Sommadossi
Abstract: A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2′,3′-dideoxy-2′,3′-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3′-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5′ or N4 alkylated or acrylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.
Abstract: The use of compounds of the formula
and pharmaceutically acceptable salts thereof, alone or in combination for the treatment of transplant rejection, wherein the substituents are further defined in the application.
Type:
Grant
Filed:
October 25, 2001
Date of Patent:
December 30, 2003
Assignee:
AtheroGenics, Inc.
Inventors:
David B. Edwards, Patricia K. Somers, Mitchell Glass
Abstract: A method for the treatment for hepatitis delta infection in a host, that includes administering an effective amount of a nucleoside or a nucleoside analog that suppresses the expression of the hepatitis B surface or preS1 antigen in the host 100-fold or more relative to pretreatment values in vivo; or to not more than 1 microgram per milliliter in vivo. In a preferred embodiment, the nucleoside is L-FMAU, or a pharmaceutically acceptable salt or prodrug thereof.
Type:
Grant
Filed:
March 29, 2001
Date of Patent:
December 30, 2003
Assignees:
Georgetown University, Cornell Research Foundation, Inc., University of Georgia Research Foundation, Inc.
Inventors:
John L. Casey, Brent E. Korba, Paul J. Cote, John L. Gerin, Bud C. Tennant, Chung K. Chu
Abstract: The present invention demonstrates that glucocorticoid-induced bone disease is due to changes in the birth and death rate of bone cells using a murine model of glucocorticoid excess as well as bone biopsy specimens obtained from patients with glucocorticoid-induced osteoporosis. This invention demonstrates that glucocorticoid administration increases apoptosis of mature osteoblasts and osteocytes and decreases bone formation rate and bone mineral density accompanied by defective osteoblastogenesis and osteoclastogenesis in the bone marrow.
Type:
Grant
Filed:
October 7, 1999
Date of Patent:
December 9, 2003
Assignee:
Board of Trustees of the University of Arkansas
Inventors:
Stavros C. Manolagas, Robert L. Jilka, Robert S. Weinstein, Teresita Bellido
Abstract: The invention concerns novel substituted 6-benzyl-4-oxopyrimidines and pharmaceutically acceptable salts thereof. These compounds inhibit reverse transcriptase encoded by human immunodeficiency virus (HIV), and are useful to prevent and treat HIV infection and acquired immune deficiency syndrome (AIDS). Pharmaceutical compositions containing the compounds and a method of use of the present compounds and other agents for the treatment of AIDS and viral infection by HIV are also envisaged.
Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.
Abstract: A compound useful for in vivo imaging of organs and tumors is provided of formula:
wherein
is a cobalamin,
is derived from a corrin carboxylic acid group of said cobalamin, Y is a linking group and X is a chelating group, optionally comprising a detectable radionuclide or a paramagnetic metal ion, and n is 1-3.
Type:
Grant
Filed:
July 26, 2000
Date of Patent:
September 2, 2003
Assignees:
Mayo Foundation for Medical Education & Research, Regents of the University of Minnesota
Inventors:
Douglas A. Collins, Henricus Petrus Hogenkamp
Abstract: Derivatives of sphingolipids of the formula:
are provided wherein the substituents are as defined in the specification and wherein there is at least one R2 substituent in the sphingolipid derivative. The compounds are useful in the treatment of of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the inhibition of protein kinase C, and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. The invention also includes a method for triggering the release of cytochrome c from mitochondria that includes administering an effective amount of a sphingolipid or its derivative or prodrug to a host in need thereof.
Type:
Grant
Filed:
February 12, 1999
Date of Patent:
August 26, 2003
Assignee:
Emory University
Inventors:
Dennis C. Liotta, Alfred H. Merrill, Jr., Thomas E. Keane, Kapil N. Bhalla, Eva M Schmelz